Short-duration triple antithrombotic therapy for atrial fibrillation patients who require coronary stenting: results of the SAFE-A study
Authors:
- Tomoya HoshiTHTomoya Hoshi
- Akira SatoASAkira Sato
- Daigo HirayaDHDaigo Hiraya
- Hiroaki WatabeHWHiroaki Watabe
- Noriyuki TakeyasuNTNoriyuki Takeyasu
- Akihiko NogamiANAkihiko Nogami
- Tomohiro OhigashiTOTomohiro Ohigashi
- Masahiko GoshoMGMasahiko Gosho
- Masaki IedaMIMasaki Ieda
- Kazutaka AonumaKAKazutaka Aonuma
- 1 June 2020
- journal article
- research article
- Published by Europa Digital & Publishing in EuroIntervention
- Vol. 16 (2) , e164-e172
Abstract
The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)Keywords
This publication has 15 references indexed in Scilit:
- 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTSEuropean Heart Journal, 2017
- Prevalence, Management, and Long-Term (6-Year) Outcomes of Atrial Fibrillation Among Patients Receiving Drug-Eluting Coronary StentsJACC: Cardiovascular Interventions, 2017
- Rationale and design of the SAFE-A study: SAFety and Effectiveness trial of Apixaban use in association with dual antiplatelet therapy in patients with atrial fibrillation undergoing percutaneous coronary interventionJournal of Cardiology, 2017
- Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCINew England Journal of Medicine, 2016
- Triple antithrombotic therapy in cardiac patients: more questions than answersEuropean Heart Journal, 2013
- Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trialThe Lancet, 2013
- A New Strategy for Discontinuation of Dual Antiplatelet TherapyJACC, 2012
- Apixaban with Antiplatelet Therapy after Acute Coronary SyndromeNew England Journal of Medicine, 2011
- Impact of CYP2C19 Polymorphisms on the Antiplatelet Effect of Clopidogrel in an Actual Clinical Setting in JapanCirculation Journal, 2009
- Clinical Significance of the Cytochrome P450 2C19 Genetic PolymorphismClinical Pharmacokinetics, 2002